Evidence map›Paper›PMID 26603102›Full record

ArticleBiochimica et biophysica acta2016

Neuronal gene repression in Niemann-Pick type C models is mediated by the c-Abl/HDAC2 signaling pathway.

Pablo S Contreras, Marcelo Gonzalez-Zuñiga, Lila González-Hódar, María José Yáñez, Andrés Dulcey, Juan Marugan, Edward Seto, Alejandra R Alvarez, Silvana Zanlungo

Open access · greenAbstract read
In one paragraph

Article in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Roles for c-Abl in postoperative neurodegeneration.International journal of medical sciences · 2022
    Review
  8. Article
  9. Understanding and Treating Niemann-Pick Type C Disease: Models Matter.International journal of molecular sciences · 2020
    Review
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Pablo S ContrerasDepartment of Cell and Molecular Biology, Pontificia Universidad Católica de Chile, Santiago, Chile; CARE UC Pontificia Universidad Católica de Chile, Santiago, Chile; Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Marcelo Gonzalez-ZuñigaDepartment of Cell and Molecular Biology, Pontificia Universidad Católica de Chile, Santiago, Chile.
Lila González-HódarDepartamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
María José YáñezDepartment of Cell and Molecular Biology, Pontificia Universidad Católica de Chile, Santiago, Chile; CARE UC Pontificia Universidad Católica de Chile, Santiago, Chile; Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Andrés DulceyNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Juan MaruganNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Edward SetoDepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Alejandra R AlvarezDepartment of Cell and Molecular Biology, Pontificia Universidad Católica de Chile, Santiago, Chile; CARE UC Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address: aalvarez@bio.puc.cl.
Silvana ZanlungoDepartamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; FONDAP Center for Genome Regulation (CGR), Santiago, Chile. Electronic address: silvana@med.puc.cl.
Pontificia Universidad Católica de Chile · CLNational Center for Advancing Translational Sciences · USMolecular Oncology (United States) · US

Funding

Small molecule screening programZ01HG200319 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI AUSTIN, CHRISTOPHER P · 2004 to 2008
$32.3M
HTS to Identify Inhibitors of c-Abl kinase for the Potential Treatment of Epilepsy and Neurodegenerative diseasesZIATR000203 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI MARUGAN, JUAN · 2015 to 2025
$3.4M
Intramural NIH HHS Z01 HG200319
6 · The paper itself

Abstract

backgroundNiemann-Pick type C (NPC) disease is a fatal neurodegenerative disorder characterized by the accumulation of free cholesterol in lysosomes. There are currently no effective FDA-approved treatments for NPC, although in the last years the inhibition of histone deacetylases (HDACs) has emerged as a potential treatment for this disease. However, the molecular mechanisms that deregulate HDAC activity in NPC disease are unknown. Previously our group had shown that the proapoptotic tyrosine kinase c-Abl signaling is activated in NPC neurons. Here, we demonstrate that c-Abl activity increases HDAC2 levels inducing neuronal gene repression of key synaptic genes in NPC models.

resultsOur data show that: i) HDAC2 levels and activity are increased in NPC neuronal models and in Npc1(-/-) mice; ii) inhibition of c-Abl or c-Abl deficiency prevents the increase of HDAC2 protein levels and activity in NPC neuronal models; iii) c-Abl inhibition decreases the levels of HDAC2 tyrosine phosphorylation; iv) treatment with methyl-β-cyclodextrin and vitamin E decreases the activation of the c-Abl/HDAC2 pathway in NPC neurons; v) in vivo treatment with two c-Abl inhibitors prevents the increase of HDAC2 protein levels in the brain of Npc1(-/-) mice; and vi) c-Abl inhibition prevents HDAC2 recruitment to the promoter of neuronal genes, triggering an increase in their expression.

conclusionOur data show the involvement of the c-Abl/HDAC2 signaling pathway in the regulation of neuronal gene expression in NPC neuronal models. Thus, inhibition of c-Abl could be a pharmacological target for preventing the deleterious effects of increased HDAC2 levels in NPC disease.

Indexed as

AnimalsCholesterolCyclodextrinsDisease Models, AnimalGene Expression RegulationHistone Deacetylase 2HumansLysosomesMiceNeuronsNiemann-Pick Disease, Type CProto-Oncogene Proteins c-ablSignal TransductionVitamin ECholesterolCyclodextrinsHDAC2 protein, humanHistone Deacetylase 2Proto-Oncogene Proteins c-ablVitamin EGNF2Histone deacetylase 2ImatinibNeuronal genesNiemann–Pick type C diseaseTyrosine kinase c-Abl

Identifiers

PMID26603102
PMCPMC5014229
OpenAlexW2207812685

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.